Adhesion molecules and proteases in epithelial ovarian cancers;Molecules d'adherence et proteases dens les cancers epitheliaux de l'ovaire

Medecine/Sciences

Volumn 15, Issue 5, 1999, Pages 645-654

  Cruet, Séverine ^a   Carreiras, Franck ^b   Staedel, Cathy ^a   Gauduchon, Pascal ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b UNIVERSITÉ DE CERGY PONTOISE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL ADHESION MOLECULE; HERMES ANTIGEN; LIGAND; MATRIX PROTEIN; PROTEINASE;

ADHERENT CELL; CELL MIGRATION; CELL PROLIFERATION; EPITHELIUM CELL; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MALIGNANT TRANSFORMATION; MESENCHYME; MESODERM; OVARY CANCER; OVULATION; PERITONEAL CAVITY; PHENOTYPE; REVIEW; SUSPENSION; TISSUE REPAIR;

EID: 0033017070     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1403     Document Type: Review

References (49)

1. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998; 3: 281-304.
2. Fathalla MF. Incessant ovulation, a factor in ovarian neoplasia? Lancet 1971; 2: 163.
3. Bullions LC, Levine AJ. The role of beta-catenin in cell adhesion, signal transduction and cancer. Curr Opin Cell Biol 1998; 10: 81-7.
4. De la Coste A, Romagnolo B, Perret C. Une dérégulation de la voie de signalisation Wnt/β-caténine impliquée dans l'hépatocarcinogenèse. Med Sci 1998; 14: 994-6.
5. Hirohashi S. Inactivation of the E-cadherin-mediated cell ahesion system in human cancers. Am J Pathol 1998; 153: 333-9.
6. Sy MS, Mori H, Liu D. CD44 as a marker in human cancers. Curr Opin Cell Biol 1997; 9: 108-12.
7. Naor D, Vogt Sionov R, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319.
8. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
9. Clezardin P. Recent insight into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998; 54:541-8.
10. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998; 10: 220-31.
11. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-24.
12. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA, Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-93.
13. Yamamoto H, Itoh F, Hinoda Y, Senota A, Yoshimoto M, Nakamura H, Yacchi A. Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin. Biochem Biophy Res Commun 1994; 201: 657-64.
14. Maines-Bandiera SL, Auersperg N. Increased E-cadherin expression in ovarian surface epithelium: an early step in metaplasia and dysplasia? Int J Gynecol Pathol 1997; 16: 250-5.
15. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, Hedin L. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 1997; 74: 275-80.
16. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopath 1998; 32: 69-80.
17. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Potet F. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopatnologic study of 60 cases. Hum Pathol 1997; 28: 922-8.
18. Veacht AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Caner 1994; 58: 393-9.
19. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, Ottensmeier C. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol. 1995; 13: 1912-21.
20. Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995; 91: 229-34.
21. Darai E, Walker-Combrouze F, Fauconnier A, Madelenat P, Potet F, Scoazec JY. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas. Histopathol 1998; 32: 151-9.
22. Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 1996; 148: 173340.
23. Strobel T, Swanson L, Cannistra SA. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 1997; 57: 1228-32.
24. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol 1995; 58: 216-25.
25. Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated bv the α2β1 integrin. Int J Cancer 1996; 67: 695-701.
26. Rieppi M, Vergani V, Allavena P, Vecchione F, Taraboletti G, Giavazzi RM. Mesothelial cells induce motility and invasion of human ovarian carcinoma cells. Proc Amer Assoc Cancer Res 1998; 39: 495.
27. Bartolazzi A, Kaczmarek J, Nicolo G, Risso AM, Tarone G, Rossino P, Defilippi P, Castellani P. Localization of the α3β1 integrin in some common epithelial tumors of the ovary and in normal equivalents. Anti-cancer Res 1993; 13: 1-12.
28. Bottini C, Miotti S, Fiorucci S, Facheris P, Ménard S, Colnaghi MI. Polarization of the α6β4 integrin in ovarian carcinomas. Int J Cancer 1993; 54: 261-7.
29. Rabinovitz I, Mercurio AM. The integrin α6β4 and the biology of carcinoma. Biochem Cell Biol 1996; 74: 811-21.
30. 3 integrin in the adhesion of the ovarian adenocarcinoma cell line IGROV1. Int J Cancer 1995; 63: 530-6.
31. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localisation of αv integrins and of their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996; 62: 260-7.
32. Carreiras F, Rigot V, Cruet S, André F, Gauduchon P, Marvaldi J. Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of αvβ3 integrins and vitronectin. Int J Cancer 1999; 80: 285-94.
33. Seiffert D. Constitutive and regulated expression of vitronectin. Histo Histopathol 1997; 12:787-97.
34. Kruk PA, Uitto VJ, Firth JD, Dedhar S, Auersperg N. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res 1994; 215: 97-108.
35. Wilson KE, Langdon SP, Lessells AM, Miller WR. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer 1996; 74: 999-1004.
36. Carreiras F, Cruet S, Staedel C, Sichel F, Gauduchon P. Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion. Gynecol Oncol 1999; 72: 312-22.
37. Liebman JM, Burbelo PD, Yamada Y, Fridman R, Kleinman HK. Altered expression of basement membrane components and collagenases in ascitic xenograft of OVCAR-3 ovarian cancer cells. Int J Cancer 1993; 55:102-9.
38. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 1995; 108: 947-56.
39. Niedbala MJ, Crickard K, Bernacki RJ. Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. Exp Cell Res 1985; 160: 499-513.
40. Schmalfeldt B, Kuhn W, Reining U, et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995; 55: 3958-63.
41. Van der Burg MEL, Henzen-Logmans SC, Berns EMJJ, Van Putten WL, Klijn JGM, Foekens JA. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in begnin, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 1996; 69: 475-9.
42. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996; 16: 150-9.
43. Young TN, Rodriguez GC, Rinehart AR, Bast RC. Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gyn Oncol 1996; 62: 89-99.
44. Afzal S, Lalani EN, Poulson R, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Path 1998; 29: 155-65.
45. Shibata K, Kikkawa F, Nawa A, Tamakoshi K, Suganuma N, Tomoda Y. Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditionned medium from human peritoneal tissue. Clin Exp Metastasis 1997; 15: 612-9.
46. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995 ; 13: 296-302.
47. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-91.
48. Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 985-92.
49. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anti-cancer strategy: a review with special Focus on batimastat and marimastat. Pharmacol Ther 1997; 75: 69-75.